LivaNova (NASDAQ:LIVN) Upgraded at Zacks Research

Zacks Research upgraded shares of LivaNova (NASDAQ:LIVN) from a hold rating to a strong-buy rating in a research note issued to investors on Tuesday morning,Zacks.com reports.

A number of other brokerages also recently weighed in on LIVN. Freedom Capital upgraded LivaNova to a “hold” rating in a report on Tuesday, June 30th. Barclays raised their price target on shares of LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Mizuho boosted their price objective on shares of LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Robert W. Baird dropped their price objective on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, KeyCorp increased their target price on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, June 22nd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $81.38.

LivaNova Stock Performance

Shares of LivaNova stock opened at $78.61 on Tuesday. LivaNova has a 12 month low of $41.01 and a 12 month high of $85.27. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. The stock has a market cap of $4.32 billion, a PE ratio of 40.31 and a beta of 0.86. The business has a fifty day simple moving average of $78.14 and a 200-day simple moving average of $69.48.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.13. The firm had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.LivaNova’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, sell-side analysts anticipate that LivaNova will post 3.73 EPS for the current fiscal year.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the transaction, the director directly owned 7,228 shares in the company, valued at $547,521. This trade represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.35% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in LIVN. GAMMA Investing LLC raised its stake in shares of LivaNova by 18.2% in the 2nd quarter. GAMMA Investing LLC now owns 1,838 shares of the company’s stock valued at $151,000 after acquiring an additional 283 shares in the last quarter. Pacer Advisors Inc. lifted its holdings in LivaNova by 4.1% in the 1st quarter. Pacer Advisors Inc. now owns 17,336 shares of the company’s stock worth $1,102,000 after purchasing an additional 675 shares during the last quarter. Segall Bryant & Hamill LLC bought a new stake in LivaNova during the first quarter worth approximately $665,000. Janus Henderson Group PLC boosted its position in LivaNova by 1,978.8% during the first quarter. Janus Henderson Group PLC now owns 471,379 shares of the company’s stock worth $29,961,000 after purchasing an additional 448,703 shares during the period. Finally, EverSource Wealth Advisors LLC grew its holdings in LivaNova by 103.6% during the first quarter. EverSource Wealth Advisors LLC now owns 1,623 shares of the company’s stock valued at $103,000 after purchasing an additional 826 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.